Designing High-Affinity Peptides for Organic Molecules by Explicit Solvent Molecular Dynamics by Gladich, Ivan et al.
1 Designing High-Aﬃnity Peptides for Organic Molecules by Explicit
2 Solvent Molecular Dynamics
3 Ivan Gladich,*,† Alex Rodriguez,† Rolando P. Hong Enriquez,‡ Filomena Guida,† Federico Berti,§
4 and Alessandro Laio*,†
5
†International School for Advanced Studies (SISSA), Via Bonomea 265, I-34136 Trieste, Italy
6
‡Istituto Italiano di Tecnologia (IIT), Genova, Italy
7
§Dipartimento di Scienze Chimiche e Farmaceutiche, University of Trieste, I-34136 Trieste, Italy
8 ABSTRACT: Short peptides oﬀer a cheap alternative to
9 antibodies for developing sensing units in devices for
10 concentration measurement. We here describe a computational
11 procedure that allows designing peptides capable of binding
12 with high aﬃnity a target organic molecule in aqueous or
13 nonstandard solvent environments. The algorithm is based on
14 a stochastic search in the space of the possible sequences of the
15 peptide, and exploits ﬁnite temperature molecular dynamics
16 simulations in explicit solvent to check if a proposed mutation
17 improves the binding aﬃnity or not. The procedure automatically produces peptides which form thermally stable complexes with
18 the target. The estimated binding free energy reaches the 13 kcal/mol for Irinotecan anticancer drug, the target considered in this
19 work. These peptides are by construction solvent specif ic; namely, they recognize the target only in the solvent in which they have
20 been designed. This feature of the algorithm calls for applications in devices in which the peptide-based sensor is required to
21 work in denaturants or under extreme conditions of pressure and temperature.
22 ■ INTRODUCTION
23 Employing speciﬁc binders with high aﬃnity and speciﬁcity
24 against target molecules is a standard technique for enhancing
25 the sensibility of concentration measurement devices. In this
26 context, peptides oﬀer an invaluable opportunity for developing
27 a cheap device capable of quickly and reliably measuring the
28 concentration of molecules, for example, of a drug or of a
29 metabolite in the blood of the patients.1−3 Indeed, the number
30 of diﬀerent properties (aﬃnity toward a target, selectivity, etc.)
31 that can be obtained by combining the natural amino acids is
32 potentially enormous, making conceivable designing peptides
33 capable of recognizing any molecule. Moreover, short peptides
34 can be easily synthesized in large quantities, making the scale-
35 up of the production of the device economically aﬀordable. The
36 opportunity of exploiting short peptides as sensing units has
37 indeed been recognized for a long time.4 Nakamura and
38 Sugimoto have been able to ﬁnd small peptides capable of
39 binding organic molecules,5,6 and some peptides have already
40 been tested for technological applications in food science as
41 receptors for electronic noses.7−11
42 Unfortunately, at variance with antibodies, peptides cannot
43 be designed exploiting the natural selection machinery. The
44 design procedure has to be developed from scratch and cannot
45 be “copied” from living organisms. This implies a major
46 challenge for theoreticians because the number of possible
47 sequences, even for a relatively small peptide with 10 residues,
48 is astronomically large, therefore calling for a computational
49 search4,12,13 based on importance sampling. However, a simple
50 random walk in the sequence space will not be suﬃcient to
51produce reliable solutions. Indeed, any automatic search also
52has to take into account the structural ﬂexibility of peptides: on
53the contrary of large proteins, peptides are extremely ﬂexible
54and their structures can change dramatically even after a single
55mutation.
56Recently, Hong et al.13 introduced an algorithm capable of
57designing peptides that bind Efavirenz, a drug used in HIV
58treatment. In this algorithm, the space of the sequences is
59explored by Monte Carlo, and viable peptide−ligand con-
60formers are obtained by ﬂexible docking, rolling the peptide on
61the target molecule and, afterward, relaxing the obtained
62structures by short molecular dynamics runs. Although this
63scheme oﬀers a valuable and computationally aﬀordable design
64solution, ﬂexible docking exploiting a scoring function
65developed to optimize complexes formed between stable
66globular proteins and a drug is unavoidably approximate for
67short peptides. Even more importantly, novel technological
68applications, such as electronic noses for drug and food
69detection,7−11 require designs in very speciﬁc environments,
70ranging from organic solvent to denaturants. To the best of our
71knowledge, the transferability of a design from one solvent to
72another has not been tested yet and a solvent speciﬁc design
73procedure is still missing.
74In this work, we introduce a novel computational procedure
75aimed at designing peptides that form thermally stable
Received: June 29, 2015
Revised: August 27, 2015
Article
pubs.acs.org/JPCB
© XXXX American Chemical Society A DOI: 10.1021/acs.jpcb.5b06227
J. Phys. Chem. B XXXX, XXX, XXX−XXX
jem00 | ACSJCA | JCA10.0.1465/W Unicode | research.3f (R3.6.i10:44431 | 2.0 alpha 39) 2015/07/15 14:30:00 | PROD-JCAVA | rq_5130466 | 9/29/2015 10:03:10 | 8 | JCA-DEFAULT
76 complexes with the target in any required environment. The
77 algorithm builds on the approach introduced by Hong et al. but
78 with several important innovations, that ﬁnally make it more
79 reliable and suitable for designing peptides in nonaqueous
80 media. First, the conformational search is carried on by ﬁnite
81 temperature molecular dynamics, exploiting a state-of-the-art
82 force ﬁeld which properly describes the ﬂexibility of both the
83 peptide and the ligand. Second, with the scope of reducing the
84 entropic contribution to the free energy of the unbound state,
85 we now design cyclic peptides with a CYS−CYS bridge
86 between the ﬁrst and the last residues. Finally, and possibly
87 most importantly, we now perform the design exploiting an
88 explicit atomistic description of the solvent. We will show that
89 this allows designing peptides capable of recognizing the target
90 in practically any kind of solvent, opening a wealth of
91 technological possibilities for developing detection and sensing
92 strategies.
93 ■ METHODOLOGY
94 The algorithm introduced in this work aims at designing short
95 cyclic peptides with high binding aﬃnity toward a target
96 organic molecule, optimizing the peptide amino acid sequence.
97 The main novelty with respect to other algorithms already
98 described in the literature12−16 is that the geometries of the
99 ligand−peptide complexes are generated by molecular dynam-
100 ics (MD) in explicit solvent. In order to benchmark this
101 approach, we performed two separated designs, one in water
102 solution and the other in methanol solution, identifying for
103 both solvents peptides capable of binding Irinotecan (CPT-
104 11),17,18 a chemotherapeutic drug whose atomic structure is
f1 105 reported in Figure 1a. The procedure is schematically described
f2 106 in the ﬂowchart in Figure 2 and consists of three computational
107 blocks: a preparation step, a mutation cycle, and a ﬁnal
108 validation step, represented, respectively, by green, blue, and
109 red blocks in Figure 2. These steps are described in detail in the
110 rest of this section.
111 Preparation Step. The procedure starts with a cyclic
112 peptide of 10 Ala closed at the end by a disulﬁde bridge
113 between the two terminal Cys. The CPT-11 molecule is
114 inserted in the middle of the ring, as displayed in Figure 1b. For
115 the design in water, the peptide−ligand complex is solvated in a
116 cubic box containing TIP3P19 water, while for the design in
117 methanol (hereafter MeOH), in a cubic box containing
118 MeOH20 molecules. All of the computational details of the
119 MD simulations are provided in the “Computational Details”
120 section below.
121The initial geometry is ﬁrst relaxed by an energy
122minimization of 50 000 steps of steepest descent method,
123keeping frozen the positions of the peptide backbone and of
124CPT-11 and allowing the relaxation of the side chains and the
125solvent. This is followed by 50 ps of constant volume (NVT)
126simulation, and ﬁnally by 10 ns of constant pressure (NPT)
127simulation. During the two MD runs, the peptide−ligand
128center-of-mass distance was constrained using a harmonic
Figure 1. Atomic structure of CPT-11. Panels b and c show CPT-11 (in orange) inserted in the peptide at the beginning and the end of the mutation
cycle, respectively.
Figure 2. Flowchart for the design algorithm. After the preparatory
stage (green blocks), ﬁve independent mutation cycles at ﬁve diﬀerent
eﬀective temperatures Te are performed, optimizing the peptide
sequence and sampling the conﬁgurational space by MD (blue blocks).
Finally, the thermal stability of the best peptide−ligand complexes is
veriﬁed by 100 ns NPT-MD simulations (red block).
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129 potential with a force constant of 700 kJ mol−1 nm−2, in order
130 to avoid the detachment of the ligand. In order to enhance the
131 sampling of the conformation space, the dynamics was carried
132 out at a temperature of 350 K. We then performed a cluster
133 analysis with the procedure in ref 21 with a cutoﬀ of 0.1 nm, on
134 the conformations generated in the last ns of dynamics, stored
135 every ps. We discarded the clusters including less than 15
136 conformations. For the centers of the other clusters, we
137 computed the value of the Vina22 scoring function. The
138 conformation with the lowest score was selected as the starting
139 state for the mutation cycle.
140 Mutation Cycle. The computational optimization of the
141 peptide sequence is based on an exploration of the sequence
142 and conﬁgurational space by combined Monte Carlo and MD
143 simulations. We attempt a single random mutation for each
144 step of the cycle and perform a ﬁnite temperature MD
145 simulation of the mutated peptide in explicit solvent to generate
146 a meaningful set of conformations. The mutation is accepted or
147 rejected according to a Metropolis criterion based on the
148 binding aﬃnity before and after the mutation. The procedure is
149 similar to the one in ref 13 but with the essential diﬀerence that
150 here the conformational search is carried out by ﬁnite
151 temperature molecular dynamics in explicit solvent, while in
152 the algorithm in ref 13 it is carried out by ﬂexible docking,
153 followed by a short MD run in a vacuum. We will show that
154 this diﬀerence signiﬁcantly aﬀects the reliability of the
155 algorithm.
156 The procedure is the following:
157 1. The peptide is randomly mutated selecting one amino
158 acid from the peptide sequence and replacing it with a
159 diﬀerent amino acid chosen at random: thus, the new
160 peptide sequence at step i + 1, SEQi+1, diﬀers from the
161 sequence at step i, SEQi, for only one amino acid. The
162 terminal CYSs are never mutated in order to conserve
163 the cyclic geometry of the peptide. The atomic
164 coordinates for the mutated peptide, ligand, and
165 solvation box were the ones of the previous step,
166 CNFi, with the only exception of the coordinate of the
167 mutated residue. In order to avoid close contacts, solvent
168 molecules that are closer than 0.2 nm from any heavy
169 atom of the mutated amino acid were removed from the
170 simulation box.
171 2. The peptide−ligand complex and its solvation box are
172 relaxed with 50 000 steps of steepest descent energy
173 minimization. Then, they are thermalized by 50 ps NVT
174 simulation and a ﬁnal production NPT run. During the
175 ﬁrst 10 mutation steps, we keep the constraint on the
176 peptide−ligand distance active, in order to avoid the
177 detachment of the complex. After the 11th step, the
178 constraint is removed. The duration of the production
179 run (tprod) is varied during the optimization, in order to
180 maximize computational eﬃciency. The ﬁrst 240
181 mutation steps, in which the binding aﬃnity drops
182 quickly, are performed with tprod = 0.6 ns. The last 120
183 mutation steps, where it is necessary generating
184 conformations that are highly thermally stable, are
185 performed with tprod = 5 ns. To enhance conformational
186 sampling, all of the MD simulations are performed at 350
187 K.
188 3. We then proceed like in the preparation step, namely, we
189 performed for the last 0.4 ns of the production run (tprod
190 = 0.6 ns) a cluster analysis with the procedure of ref 21,
191with a cutoﬀ of 0.1 nm, discarding the clusters including
192less than 15 conformations. We then compute the value
193of the Vina22 scoring function for the centers of the other
194clusters. The conformation with the lowest score is
195selected. We denote by Ei+1 its score and by CNFi+1 the
196atomic coordinates of the peptide, the ligand, and the
197solvation box. In the last 120 steps of the design, the ones
198performed with a production time of tprod = 5 ns, Ei+1 is
199computed as the average Vina score in the last 1 ns of the
200trajectory. This requires docking a large number of
201peptide−ligand conformers, resulting in a higher
202computational cost, but it provides a more accurate
203estimate of the binding aﬃnity. This is beneﬁcial in the
204ﬁnal part of the optimization, where it is essential
205selecting only mutations that allow very stable complex-
206es.
2074. The new state (CNFi+1, SEQi+1, Ei+1) is accepted or
208rejected according to a Metropolis criterion, with a
209probability of min(1, exp[(E1 − E0)/Te]). Te is an
210eﬃcacious temperature that controls the acceptance rate.
211In the case of acceptance, the new step started from
212(CNFi+1, SEQi+1, Ei+1); otherwise, from the previous state
213(CNFi, SEQi, Ei).
214The mutation cycle described above was iterated up to a
215desired number of mutations. Consistently with ref 13, we
216strengthened the exploration of the sequence space by
217performing ﬁve simultaneous and independent mutation cycles
218at ﬁve eﬃcacious temperatures Te = 0.2, 0.4, 0.6, 0.8, and 1.0
219kcal/mol. At the end of each mutation step, two replicas r and
220r′ are selected at random and an exchange between their Te’s
221was attempted according to a parallel tempering scheme:23 a
222swap between the states of replica r at Tr (CNFr, SEQr, Er) and
223the state of replica r′ at Tr′ (CNFr′, SEQr′, Er′) is accepted with
224a probably of min(1, exp[(Er − Er′)]/(1/Tr − 1/Tr′)).
225Validation Step. After reaching the required number of
226mutations or the desired binding aﬃnity, the best structures
227and sequences are selected to benchmark their thermal stability.
228For such structures, we perform 100 ns NPT simulations at 300
229K by monitoring the peptide−ligand center-of-mass distance
230and the Vina aﬃnity. As we will show in the following, this
231validation step is essential for judging the quality of the
232solutions of the algorithm.
233Computational Details. In all of the MD simulations, the
234intramolecular and nonbonded interactions are described
235according to the GAFF force ﬁeld24 for CPT-11 and
236AMBER-99SB20 for the peptide and MeOH. Consistently
237with the GAFF practice, the Lorentz−Berthelot combination
238rule is adopted for the nonbonded interaction expressed in
239terms of the Lennard-Jones potential. The electrostatic
240interaction was described by the Coulomb potential between
241partial charges at individual atom sites. For MeOH and the
242peptide chain, the partial charges were adopted from the
243AMBER-99SB force ﬁeld while the CPT-11 ones were obtained
244by the AM1-BCC method25 implemented in Antechamber.26
245All MD simulations were performed using GROMACS
2464.6.727 with GPU card support. The MD runs were carried out
247using a time step of 2 fs. The temperature was controlled by a
248stochastic velocity rescaling thermostat28 with a coupling time
249of 0.1 ps, while, for the NPT run, a Berendsen pressure
250coupling29 with a coupling constant of 2 fs was used, keeping
251the pressure at 1 bar. Standard 3D periodic boundary
252conditions were adopted with a cutoﬀ distance of 1.0 nm on
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253 the real-space Coulomb and the van der Waals interactions,
254 updating the neighbor list according to the Verlet cutoﬀ
255 scheme. The long-range part of the Coulomb interactions was
256 evaluated using the particle-mesh Ewald method with a relative
257 tolerance of 10−5, fourth order cubic interpolation, and a
258 Fourier spacing parameter of 0.16. All bonds were constrained
259 using LINCS, while SETTLE was used for constraining the
260 water molecules. With the above setup, we were able to
261 perform about 10 mutations/day for each temperature replica,
262 using an 8 Hyper-threading IntelXeon 2.6 GHz with one Titan
263 Black GPU card and a MD trajectory of tprod = 5 ns.
264 ■ RESULTS AND DISCUSSION
265 Our algorithm aims at designing cyclic peptides of high aﬃnity
266 toward a target molecule. The main innovation introduced in
267 this work is using MD simulations for sampling the most
268 relevant peptide−ligand conformations. This allows designing
269 the peptides in an explicit solvent environment. We here show
270 that this innovation is crucial in order to obtain peptides that
271 are able to form a stable complex with the target. We
272 demonstrate this by comparing our algorithm (MD-algorithm
273 hereafter) with the one in ref 13, that uses ﬂexible docking to
274 generate the conformations (FD-algorithm hereafter). This
f3 275 comparison is reported in Figure 3. The outcome of the
276 mutation cycle, i.e., the binding aﬃnity Ei as a function of
277 mutation iteration i, for all eﬀective temperatures Te, is
278displayed in Figure 3a and c for the FD-algorithm13 and our
279new scheme, respectively. We run both algorithms starting from
280the same initial conformation, a SA10S chain surrounding the
281ligand (see Figure 1b). At the beginning, the binding aﬃnity is
282approximately −6 kcal/mol in both cases. Since SA10S is not a
283good binder for CPT-11, in the ﬁrst step of the optimization of
284the MD-algorithm, the peptides show the tendency to detach
285from the ligand during the MD simulation. We therefore
286impose a constraint on the peptide−ligand center-of-mass
287distance for a suﬃcient number of mutations. After 10 steps,
288the sequence of the peptide starts adapting to the ligand, and
289the complex becomes stable for the duration of the MD run
290used in the design (600 ps). Therefore, the constraint can be
291removed. Imposing the constraint is not necessary in the FD-
292algorithm, since in that case MD is used only to avoid close
293contacts between the ligand and the newly mutated structure,
294without addressing possible structural thermal instabilities at
295long times.
296Both algorithms predict a maximum binding aﬃnity of about
297−14 kcal/mol, which corresponds to the energy plateau
298observed in Figure 3a and c: The FD-algorithm reaches this
299value in about 700 mutations, while the new scheme, in less
300than 300 steps. However, a mutation step in the FD-algorithm
301is approximately 6−7 times faster than that in the MD-
302algorithm, since the latter requires performing a MD run in
303explicit solvent at each step. Figure 3c shows a slightly upward
304jump in the estimated aﬃnities after 250 mutations. We
305rationalized this jump by the fact that we switched the
306production run from 0.6 to 5 ns simulation time after 250
307mutations. During the 0.6 ns production runs, the system is at
308times unable to equilibrate suﬃciently, allowing the Monte
309Carlo procedure to accept some mildly metastable conﬁg-
310urations. On the other hand, carrying out all the optimizations
311using an equilibration time of 5 ns would be too computa-
312tionally expensive. For this reason, we decided to perform the
313ﬁrst part of the design using shorter runs, tprod = 0.6 ns, and,
314afterward, complete the design with longer runs, allowing a
315longer time for equilibration.
316It is worth noticing that the maximum binding aﬃnity
317reachable by the design procedure is strongly aﬀected by the
318 f4starting conﬁguration. Figure 4 shows the result of a design in
319water in which the CPT-11 molecule was initially placed on the
320top of the SA10S ring: the maximum binding after 100
321mutations is about −8.5 kcal/mol, while the optimization
322carried out with the target inserted in the ring (Figure 3c)
323reaches −13 kcal/mol in the same number of iterations.
324Moreover, we never observed during this design an event in
325which the target inserts in the ring. We cannot rule out the
326possibility that, with longer simulation time, the CPT-11 could
327spontaneously enter the peptide ring, but it seems that this
328conﬁgurational rearrangement is unlikely during our simulation
329time. This allows concluding that the initial conformation has
330indeed an important impact on the optimization procedure. For
331CPT-11, the optimal starting conﬁguration was the one with
332the ligand inserted in the peptide ring; however, it is reasonable
333to suppose that the best starting conﬁguration will be, in
334general, target speciﬁc.
335The most remarkable diﬀerence between the two algorithms
336is the quality of the solutions they are able to ﬁnd in terms of
337thermal stability. We selected the best seven peptides found by
338the FD- and by the MD-algorithm, which diﬀer among them
339for at least ﬁve amino acids. For these 14 complexes, we then
340performed a 100 ns MD simulation in water solution, starting
Figure 3. Optimization and test of peptides designed according the
FD-algorithm of Hong et al. (a and b) and the MD-algorithm
presented in this work (c and d). Panels a and c: the Vina scoring
function as a function of the mutation step. Diﬀerent colors
correspond to diﬀerent replicas. Panels b and d: the value of the
scoring function for the seven best peptides estimated in the design
cycle (black points) and estimated as the average on the last 80 ns of
100 ns MD simulations in explicit solvent (blue squares). The vertical
dashed purple line in panel c indicates where the production time, tprod,
was switched from 0.6 to 5 ns. The sequences are reported in Table 1.
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341 from the structures generated by the two algorithms (see the
342 Methodology section). For each complex, we then compute the
343 average binding aﬃnity in the last 80 ns of the simulation. If the
344 peptide−ligand complex is thermally unstable, the peptide
345 tends to detach and the Vina aﬃnity, that by construction
346 always starts from approximately −13 kcal/mol, tends to drift
347 toward higher values. The results of this analysis are illustrated
348 in Figure 3b and d. The black points are the aﬃnities estimated
349 in the mutation cycle, while the blue squares indicate the
350 averages over the MD trajectory. Figure 3b clearly shows that
351 the peptides designed by the FD-algorithm tend to detach from
352 the ligand when the complex is solvated in water and evolved
353 by MD. All the peptides show this upward drift, that is of
354 approximately 4 kcal/mol in the worst cases. This indicates that
355 ﬂexible docking is capable of eﬃciently generating structures of
356 high estimated binding aﬃnity, but these structures are not
357 stable at ﬁnite temperature and in a realistic solvent
358 environment. On the contrary, as shown in Figure 3d, the
359 MD-algorithm generates peptides that under the same
360 conditions are stable, with an average binding aﬃnity very
361 close to the one obtained during the design cycle in almost all
t1 362 cases. The analysis of the peptide sequences in Table 1 shows
363 that peptides designed with the new scheme are richer in
364 aromatic residues than the ones designed by the FD-algorithm,
365 that are on average 6 for the former and 3 for the latter.
366 Apparently, the explicit water description favors the selection of
367 aromatic residues, which are repelled by water and bind toward
368 the aromatic groups of CPT-11, enhancing the binding aﬃnity.
369 Another major advantage of an algorithm based on molecular
370 dynamics in explicit solvent is that it allows designing peptides
371 capable of binding a target in any given solvent. This feature is
372 useful if one exploits the algorithm for designing peptides that
373 can be embedded in a sensor, since in several cases these
374 devices work under very speciﬁc physicochemical conditions,
f5 375 for example, in a denaturant. Figure 5 shows that, not
376 surprisingly, peptides which bind well in one type of solvent
377 do not necessarily bind in another one. The ﬁgure reports the
378 binding of the peptides designed in water (blue squares) once
379 they are solvated in MeOH (green diamond). The peptide−
380 ligand binding is substantially weaker when they are solvated in
381 an environment (MeOH) which is diﬀerent from the one of the
382original design (water). In Figure 5b, we report the Vina
383binding aﬃnity in water (blue curve) and MeOH (green) as a
384function of time for peptide A, whose primary sequence is
385reported in Table 1. The ﬁgure shows that the aﬃnity is stable
386in water solution, while it drifts upward in MeOH. The
387inspection of the trajectory further proves the instability of the
388peptide−ligand complexes designed in water and solvated in
389MeOH: Figure 5c shows the backbone of peptide A together
390with CPT-11 at 0, 25, 50, 75, and 100 ns, showing that the
391peptide is undergoing severe structural changes. A similar trend
392has been observed for all the other peptides designed in water
393and solvated in MeOH reported in Table 1. On the other hand
394and consistently with what we saw in water, peptides designed
395in MeOH are stable in MeOH: Figure 5d shows the binding
396aﬃnity of the seven best peptides designed in MeOH. The Vina
397binding aﬃnity as a function of time (Figure 5e) and the
398structures explored by the peptide−ligand complex (Figure 5f)
399conﬁrm that peptides deigned in MeOH form remarkably
400stable complexes in the same solvent. The solvent speciﬁcity of
401the design is also conﬁrmed by the composition of the best
402peptide sequence (see Table 1). The average number of
403aromatic residues is smaller for the design in MeOH (about 4)
404than for the design in water (about 6): MeOH is a less polar
405solvent than water, and thus, aromatic side chains can be more
406easily exposed to MeOH, competing with the binding toward
407CPT-11.
408The stability of the obtained complexes was further
409benchmarked carrying out extra 100 ns MD runs at higher
410temperature (350, 400, and 450 K) for the best structures in
411water and MeOH, i.e., peptide-A and peptide-α in Table 1. The
Figure 4. Optimization of peptides designed in explicit water
according to the MD-algorithm, starting from an initial conﬁguration
in which the CPT-11 is not inserted in the ring but it lays on the poly-
alanine chain. Similarly to Figure 3c, the ﬁgure shows the Vina scoring
function as a function of the mutation step and for diﬀerent
temperature replicas. The maximum estimated binding aﬃnity is
about −8.5 kcal/mol; the comparison with Figure 3c shows that the
performance of the design procedure is dependent from the chosen
starting conﬁguration.
Table 1. Peptide Sequence and Binding Aﬃnities for the
Designs toward CPT-11a
FD-algorithm sequence EDesign E100ns
0 CTPRKNWGWGYC −14.0 −10.7
1 CTTRKGWGWGYC −13.6 −10.3
2 CGWWNPGQGWDC −13.1 −9.6
3 CVGQWEENWYGC −12.4 −8.8
4 CGHWYPGQDSDC −12.3 −9.3
5 CVSWNQFPTFQC −12.0 −10.2
6 CWEPWEENWMGC −12.0 −9.6
MD-algorithm-WATER sequence EDesign E100ns
A CFYWNYQYHVFC −13.5 −13.0
B CNYYNYTWFVYC −13.3 −13.1
C CFFWNYVYWRKC −12.7 −12.3
D CKYWRLVYWFFC −12.1 −9.6
E CFVWIWLYWFRC −11.0 −10.9
F CQFNEHVHWFAC −10.5 −9.9
G CSHRWMHWRHEC −9.9 −9.8
MD-algorithm-MeOH sequence EDesign E100ns
α CQYQKYIYYKYC −13.2 −12.6
β CWYWALIIYVRC −13.0 −12.6
γ CWYTQEMPYDYC −12.7 −12.2
δ CWYSYNAMYRYC −12.6 −11.0
ϵ CWNQHYQEYKYC −12.6 −12.7
ζ CQVQYSIQYYYC −12.3 −11.4
η CHVQYYNPYDVC −11.5 −11.6
aFor all three designs, i.e., the FD-algorithm of Hong et al. and the
MD-algorithm in explicit water and MeOH, the table reports the
amino acid sequence of the seven best peptides and their binding
aﬃnities, during the mutation cycle (EDesign) and during the last 80 ns
of a 100 ns MD simulation (E100ns).
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412 Vina scores for these two peptides at diﬀerent temperatures in
f6 413 water and MeOH are reported in Figure 6a and b, respectively.
414 As expected, at higher temperature, the contacts between the
415 two molecules are weaker, and some are even broken. However,
416 even at 400 K, the ligand keeps several contacts with the
417 peptide during the entire 100 ns of the simulation, indicating
418 that the complex is remarkably stable. This is remarkable, since
419 complexes formed by peptides with a lower estimated binding
420 aﬃnity are normally unstable even at 300 K, while only the
421 complexes optimized using the procedure described in the
422manuscript are able to survive systematically 100 ns of MD. In
423this respect, it should be noted that Vina22 estimates aﬃnities
424by counting the number and type of peptide−ligand contacts
425and assigning, to each of them, an energy value assuming a
426water environment. For this reason, the docking aﬃnities are
427not necessarily meaningful in nonaqueous environment.
428However, we observed a clear correlation between the binding
429aﬃnity, the number of apolar and polar contacts, and the
430peptide−drug center-of-mass distance. Moreover, the docking
431score was not used here with the intent of generating viable
432conformers but only as a measure of the peptide−ligand
433stability, screening the MD conformations. For all of these
434reasons, the docking score should be considered only a rough
435estimate of the binding aﬃnity, especially in nonaqueous
436environment. Future work is planned to develop a new scoring
437function capable of estimating the binding aﬃnity in a
438nonaqueous environment.
439■ CONCLUSIONS
440Small peptides capable of binding organic molecules have
441recently emerged as valuable solutions for the development of
442new biosensors in medical and technological areas. The large
443number of possible sequences, even in short peptides, call for
444automatic in silico approaches capable of ﬁnding the best
445sequence for a given target. Some algorithms have been
446proposed in the literature, but the generation of possible
447peptide−ligand complex geometries is normally based on
448docking protocols. The thermal stability in explicit solvent of
449the obtained peptide−ligand complexes can always be checked
450a posteriori, or experimentally, but an algorithm capable of
451ﬁnding a solution whose reliability is automatically ensured
452would be desirable.
Figure 5. Comparison between the design in explicit water and explicit MeOH. Similarly to Figure 3, panel a shows the binding aﬃnities for the
seven best peptides designed in water (see Table 1) as they come out from the design (black points), after 100 ns MD in explicit water (blue
squares), and after 100 ns MD in explicit MeOH (green diamonds). Panel b reports the Vina score as a function of time for the peptide-A/CPT-11
in water (blue) and MeOH (green). Panel c illustrates the peptide A backbone positions around CPT-11 (in orange) at 0, 25, 50, 75, and 100 ns
(blue, purple, green, yellow, and red, respectively). Panels d, e, and f are the equivalent of panels a, b, and c, respectively, for the design in MeOH.
The score as a function of time and the structures are shown for the peptide-α/CPT-11 complex. The amino acid sequences for peptide-A and
peptide-α are reported in Table 1.
Figure 6. Thermal stability at diﬀerent temperatures for peptide-A and
peptide-α in water and MeOH, respectively. Panel a reports the Vina
score as a function of time for the peptide-A/CPT-11 complex in
water at 300 K (blue), 350 K(green), 400 K (orange), and 450 K
(red). Similarly, panel b shows the Vina binding over 100 ns for the
peptide-α /CPT-11 complex in MeOH.
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453 In this work, we presented a novel computational procedure
454 for designing high-aﬃnity peptides based on molecular
455 dynamics in a explicit solvent environment. This procedure
456 relies on ﬁnite temperature MD simulations, which generate
457 viable peptide−ligand structures properly describing the
458 ﬂexibility of both the peptide and ligand. Designing cyclic
459 peptides allows reducing the entropic contribution to the
460 binding aﬃnity, which is usually poorly described by the scoring
461 functions. All of these new features have enabled peptides to be
462 designed which are thermally stable on a 100 ns time scale in a
463 realistic solvent environment, opening (in principle) the
464 possibility of designing high-aﬃnity peptides for any kind of
465 target in any kind of solvent. The procedure could be further
466 improved by exploiting a scoring function targeted for
467 nonaqueous solvents: future work is currently planned in this
468 direction. Nevertheless, we strongly believe that the computa-
469 tional design scheme presented here already has potential for
470 exciting technological applications, from food science to drug
471 recognition, in which peptide-based sensors are required to
472 work, for example, in denaturants or under extreme conditions
473 of pressure and temperature.
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